BSE Live
Dec 26, 16:01Prev. Close
5563.80
Open Price
5563.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 26, 15:56Prev. Close
5566.00
Open Price
5539.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
5535.00 (39)
| Balance Sheet of Alkem Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 23.91 | 11.96 | 11.96 | 11.96 | 11.96 | |
| Total Share Capital | 23.91 | 11.96 | 11.96 | 11.96 | 11.96 | |
| Reserves and Surplus | 3,076.80 | 2,703.00 | 2,290.78 | 1,851.79 | 1,447.77 | |
| Total Reserves and Surplus | 3,076.80 | 2,703.00 | 2,290.78 | 1,851.79 | 1,447.77 | |
| Total Shareholders Funds | 3,100.71 | 2,714.96 | 2,302.74 | 1,863.75 | 1,459.73 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 28.13 | 53.92 | 92.28 | 127.19 | 66.89 | |
| Deferred Tax Liabilities [Net] | 66.77 | 44.06 | 48.04 | 33.55 | 22.81 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 61.66 | 47.35 | 49.40 | 50.60 | 49.83 | |
| Total Non-Current Liabilities | 156.56 | 145.33 | 189.72 | 211.34 | 139.53 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 1,046.28 | 845.22 | 1,093.75 | 671.57 | 661.13 | |
| Trade Payables | 342.52 | 276.05 | 254.34 | 259.02 | 163.24 | |
| Other Current Liabilities | 153.62 | 169.84 | 124.42 | 97.77 | 83.61 | |
| Short Term Provisions | 66.65 | 50.16 | 46.25 | 62.73 | 63.66 | |
| Total Current Liabilities | 1,609.07 | 1,341.27 | 1,518.76 | 1,091.09 | 971.64 | |
| Total Capital And Liabilities | 4,866.34 | 4,201.56 | 4,011.22 | 3,166.18 | 2,570.90 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 966.35 | 909.39 | 832.06 | 664.92 | 484.31 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 966.35 | 909.39 | 832.06 | 664.92 | 484.31 | |
| Non-Current Investments | 1,010.65 | 691.04 | 513.22 | 348.36 | 16.54 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 646.39 | 498.90 | 380.53 | 266.84 | 127.02 | |
| Other Non-Current Assets | 460.12 | 782.68 | 292.72 | 676.53 | 460.41 | |
| Total Non-Current Assets | 3,083.51 | 2,882.01 | 2,018.53 | 1,956.65 | 1,088.28 | |
| CURRENT ASSETS | ||||||
| Current Investments | 59.91 | 248.95 | 66.19 | 23.81 | 36.63 | |
| Inventories | 548.24 | 504.56 | 452.80 | 309.22 | 227.92 | |
| Trade Receivables | 375.01 | 290.32 | 291.81 | 251.71 | 162.15 | |
| Cash And Cash Equivalents | 633.32 | 122.76 | 965.18 | 493.25 | 980.17 | |
| Short Term Loans And Advances | 119.47 | 120.21 | 129.18 | 86.41 | 39.68 | |
| OtherCurrentAssets | 46.88 | 32.75 | 87.53 | 45.13 | 36.07 | |
| Total Current Assets | 1,782.83 | 1,319.55 | 1,992.69 | 1,209.53 | 1,482.62 | |
| Total Assets | 4,866.34 | 4,201.56 | 4,011.22 | 3,166.18 | 2,570.90 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 400.32 | 358.91 | 530.69 | 376.77 | 276.47 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 120.72 | 120.42 | 60.67 | 42.55 | 36.75 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 14.12 | 6.14 | 26.08 | 27.68 | 10.45 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 113.44 | 83.49 | 56.50 | 37.29 | 26.95 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 344.38 | 277.52 | 225.39 | 170.26 | 151.94 | |
| Other Earnings | 7.24 | 31.96 | 28.03 | 4.79 | 1.61 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 11.96 | 5.98 | 5.98 | 5.98 | 5.98 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 164.12 | 59.77 | 270.28 | 252.47 | 3.06 | |
| Non-Current Investments Unquoted Book Value | 852.88 | 631.27 | 242.94 | 95.89 | 13.95 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 10.12 | 253.45 | 29.21 | 25.66 | 43.94 | |
| Current Investments Unquoted Book Value | 51.75 | -- | -- | -- | -- |
04.12.2025
Alkem Lab Consolidated September 2025 Net Sales at Rs 4,000.99 crore, up 17.17% Y-o-Y
24.11.2025
Alkem Lab Standalone September 2025 Net Sales at Rs 2,542.03 crore, down 11.49% Y-o-Y
10.09.2025
Alkem Lab Standalone June 2025 Net Sales at Rs 2,372.17 crore, down 5.12% Y-o-Y
12.08.2025
Q1 Results impact: Alkem Labs, PN Gadgil shares rally up to 10% on strong earnings, Granules up 4%
12.07.2023
Alkem Laboratories Q1 PAT seen up 135.1% YoY to Rs 299.7 cr: Nirmal Bang
17.10.2018
Alkem Labs Q2 PAT may dip 30.2% YoY to Rs. 220 cr: HDFC Securities
20.04.2018
Alkem Labs Q4 PAT may dip 1.5% YoY to Rs. 130 cr: HDFC Securities
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key